<DOC>
	<DOCNO>NCT02519348</DOCNO>
	<brief_summary>This multicenter , open-label , stratified , randomize study evaluate safety , tolerability , antitumor activity , PK , pharmacodynamics , immunogenicity MEDI4736 ( Durvalumab ) combination tremelimumab , MEDI4736 monotherapy tremelimumab monotherapy subject unresectable hepatocellular carcinoma</brief_summary>
	<brief_title>A Study MEDI4736 With Tremelimumab , MEDI4736 Tremelimumab Monotherapy Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Male female subject 2 . 18 year old ( Japan20 year older ) 3 . Confirmed diagnosis unresectable hepatocellular carcinoma without concomitant viral hepatits B hepatitis C infection . 4 . Immunotherapynaive either progressed , intolerant , refuse treatment sorafenib . Subjects receive treatment systemic therapy sorafenib eligible . 1 . Prior exposure immunemediated therapy 2 . Hepatic encephalopathy characterize asterixis 3 . Active prior document gastrointestinal variceal bleed 4 . Ascites require nonpharmacologic intervention escalation pharmacologic intervention maintain symptom control 5 . Main portal vein thrombosis 6 . Any concurrent chemotherapy , immunotherapy , biologic hormonal therapy cancer treatment 7 . Active prior document autoimmune inflammatory disease exception 8 . Current prior use immunosuppressive medication within 14 day exception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Tremelimumab</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Durvalumab</keyword>
</DOC>